About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

HilleVax, Inc. - Common Stock (NQ: HLVX )

1.715 +0.085 (+5.21%)
Streaming Delayed Price Updated: 3:49 PM EDT, Jul 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about HilleVax, Inc. - Common Stock

< Previous 1 2 3 Next >
(HLVX) - Analyzing HilleVax's Short Interest
Via Benzinga
HilleVax, Inc. (HLVX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Gold Falls Over 1%; HilleVax Shares Plunge
Via Benzinga
Stocks Hold Steady, Small Caps Rise, French Equities Slip After Surprise Win By Left-Wing Bloc: What's Driving Markets Monday?
U.S. stocks started the week on a neutral note, with the S&P 500 and Nasdaq 100 indices hovering around the flatline by midday trading in New York. This comes after both indices reached fresh record... 
Via Benzinga
HLVX Stock Earnings: HilleVax Beats EPS for Q4 2023
HLVX stock results show that HilleVax beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Recap: HilleVax Q4 Earnings
Via Benzinga
Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
GRFS Stock Alert: Grifols Pops 20% on Takeover Interest
Grifols stock is up on Monday as the founding family of the company has presented a preliminary takeover offer for GRFS shares. 
Via InvestorPlace
Why Is HilleVax (HLVX) Stock Down 87% Today?
HilleVax stock is down on Monday after HLVX investors learned of a failed Phase 2b clinical trial of its norovirus vaccine for infants. 
Via InvestorPlace
HLVX Investors Have Opportunity to Join HilleVax, Inc. Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Dow Turns Lower; Myomo Shares Jump
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Jumps Over 200 Points; Greenbrier Shares Fall After Q3 Results
Via Benzinga
Topics Stocks
Exposures US Equities
Vaccine Developer HilleVax Stock Nosedives On Monday - Here's Why
Shares of HilleVax fell after the release of Phase 2b trial results for HIL-214, a vaccine for norovirus-related acute gastroenteritis in infants. The study showed 5% efficacy and no significant... 
Via Benzinga
HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants
From HilleVax, Inc.
Via GlobeNewswire
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Saia, Annexon, Core Scientific And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
HLVX Stock Earnings: HilleVax Misses EPS for Q1 2024
HLVX stock results show that HilleVax missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress
From HilleVax, Inc.
Via GlobeNewswire
HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer
From HilleVax, Inc.
Via GlobeNewswire
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will... 
Via Talk Markets
HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China
Collaboration leverages HilleVax’s leading norovirus vaccine development expertise and adds a Phase 1-ready next-generation program to HilleVax’s pipeline 
From HilleVax, Inc.
Via GlobeNewswire
HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
From HilleVax, Inc.
Via GlobeNewswire
HilleVax to Present at Upcoming Investor Conferences
From HilleVax, Inc.
Via GlobeNewswire
HilleVax to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From HilleVax, Inc.
Via GlobeNewswire
Why HilleVax Shares Are Trading Lower
HilleVax Inc (NASDAQ: HLVX) shares are trading lower by 8.5% to $13.20 Wednesday morning after the company announced pricing of its previously-announced public offering of comm 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.